Development and Validation of a Fluorescence Polarization-Based Competitive Peptide-Binding Assay for HLA-A*0201A New Tool for Epitope Discovery
- 26 August 2005
- journal article
- research article
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 44 (37) , 12491-12507
- https://doi.org/10.1021/bi050255v
Abstract
Various approaches are currently proposed to successfully develop therapies for the prevention and treatment of infectious diseases and cancer. One of the most promising approaches is the development of vaccines that elicit cytotoxic T lymphocyte (CTL) responses. Consequently, identification and exact definition of molecular parameters involved in peptide-MHC class-I interactions of putative CTL epitopes are of prime importance for the development of immunomodulating compounds. To better facilitate epitope discovery, we developed and validated a novel state-of-the-art biochemical HLA-A0201 assay, which is comprised of technologically advanced cutting edge reagents. The technique is based on competition and uses a FITC-labeled reference peptide and highly purified soluble HLA-A0201 molecules to quantitatively measure the binding capacity of nonlabeled peptide candidates. Detection by fluorescence polarization allows real-time measurement of binding ratios without separation steps. During standardization, the problem of assay parameter variation is discussed, showing the dramatic influence of HLA and reference peptide concentrations as well as the choice of the reference peptide itself on IC(50) determinations. For validation, a panel of 15 well-defined HLA-A0201 ligands from various sources covering a broad range of binding affinities was tested. Binding data were used to compare against pre-existing quantitative assay systems. The results obtained demonstrated significant correlation among assay procedures, suggesting that the application of fluorescence polarization in combination with recombinant sHLA molecules is highly advantageous for the accurate assessment of peptide binding. Furthermore, the assay also features high-throughput screening capacity, providing uniquely efficient means of identifying and evaluating immune target molecules.Keywords
This publication has 35 references indexed in Scilit:
- TCR reconstitution in Jurkat reporter cells facilitates the identification of novel tumor antigens by cDNA expression cloningInternational Journal of Cancer, 2002
- Tumor Eradication by Wild-type p53-specific Cytotoxic T LymphocytesThe Journal of Experimental Medicine, 1997
- Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigenEuropean Journal of Immunology, 1996
- Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines.The Journal of Experimental Medicine, 1996
- Differences and similarities in the A2.1‐restricted cytotoxic T cell repertoire in humans and human leukocyte antigen‐transgenic miceEuropean Journal of Immunology, 1996
- Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA moleculesEuropean Journal of Immunology, 1995
- Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans.Journal of Clinical Investigation, 1995
- The assembly of H2‐Kb class I molecules translated in vitro requires oxidized glutathione and peptideEuropean Journal of Immunology, 1993
- Peptides Naturally Presented by MHC Class I MoleculesAnnual Review of Immunology, 1993
- Cytotoxic T-Cell Immunity to InfluenzaNew England Journal of Medicine, 1983